BIOMEDICAN Announces Organic Biosynthesis of Rare Cannabinoid THCV/THCVA
SAN FRANCISCO, November 19, 2020 (Newswire.com) - BIOMEDICAN, a biotech company designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts, has successfully biosynthesized rare cannabinoid THCV/THCVA. The product is pharmaceutical- grade, 100% organic, non-GMO, and bioidentical to the molecules occurring in nature, with production costs that are over 90% less than current wholesale prices.
THCV/THCVA (not to be confused with THC) is among the most effective and sought-after rare cannabinoids. Research has demonstrated its potential to treat a variety of conditions, including Alzheimer’s, diabetes, and osteoporosis. With its wide range of health benefits, THCV/THCVA is desired by a variety of industries, including nutraceuticals, CBD, health food, and cosmetics.
“The nutraceutical, CBD, health food, and cosmetics markets are beginning to understand the significant health benefits of THCV/THCVA. This allows them to differentiate themselves from crowded marketplaces and, more importantly, deliver healthier products,” says BIOMEDICAN CEO Maxim Mikheev. “We are in discussions with pharmaceutical companies pertaining to using BIOMEDICAN’s THCV/THCVA in upcoming clinical trials.”
THCV/THCVA naturally occurs in such trace amounts that it is challenging to manufacture economically with high purity levels. The only way to produce high-purity, pharmaceutical-grade, toxin- and contaminant-free, low-cost THCV/THCVA at scale is via biosynthesis.
The biosynthetic cannabinoid market is expected to reach $10 billion by 2025. With its strong health properties and applications to numerous industries, THCV/THCVA will represent one of the top three cannabinoids in market share.
“THCV/THCVA is beginning to build a considerable amount of interest from well-informed consumers who are realizing the significant health benefits of this rare cannabinoid,” adds Mikheev. “Much like how CBD evolved from an unknown substance to one that’s now sold in hundreds of thousands of retail locations, we believe the same will happen with THCV/THCVA.”
BIOMEDICAN is a biotech company designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts. Our patented biosynthetic methods ensure the efficient production of high-quality compounds using the fermentation of unique proprietary yeast. In contrast to chemically synthesized, our natural, organic, non-GMO biosynthetic compounds are 100% identical to those found in nature, while free from undesired byproducts.
Dennis O’Neill, President
Jon Lindsay Phillips, COO
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bio-synthesized cannabinoids or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.